Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
JAMA Neurol ; 80(7): 732-738, 2023 07 01.
Article in English | MEDLINE | ID: mdl-37252708

ABSTRACT

Importance: Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of alteplase for stroke thrombolysis based on evidence from randomized comparisons to alteplase as well as for its practical advantages. There have been no significant differences in symptomatic intracranial hemorrhage (sICH) reported from randomized clinical trials or published case series for the 0.25-mg/Kg dose. Objective: To assess the risk of sICH following ischemic stroke in patients treated with tenecteplase compared to those treated with alteplase. Design, Setting, and Participants: This was a retrospective observational study using data from the large multicenter international Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) collaboration comprising deidentified data on patients with ischemic stroke treated with intravenous thrombolysis. Data from more than 100 hospitals in New Zealand, Australia, and the US that used alteplase or tenecteplase for patients treated between July 1, 2018, and June 30, 2021, were included for analysis. Participating centers included a mix of nonthrombectomy- and thrombectomy-capacity comprehensive stroke centers. Standardized data were abstracted and harmonized from local or regional clinical registries. Consecutive patients with acute ischemic stroke who were considered eligible and received thrombolysis at the participating stroke registries during the study period were included. All 9238 patients who received thrombolysis were included in this retrospective analysis. Main Outcomes and Measures: sICH was defined as clinical worsening of at least 4 points on the National Institutes of Health Stroke Scale (NIHSS), attributed to parenchymal hematoma, subarachnoid, or intraventricular hemorrhage. Differences between tenecteplase and alteplase in the risk of sICH were assessed using logistic regression, adjusted for age, sex, NIHSS score, and thrombectomy. Results: Of the 9238 patients included in the analysis, the median (IQR) age was 71 (59-80) years, and 4449 patients (48%) were female. Tenecteplase was administered to 1925 patients. The tenecteplase group was older (median [IQR], 73 [61-81] years vs 70 [58-80] years; P < .001), more likely to be male (1034 of 7313 [54%] vs 3755 of 1925 [51%]; P < .01), had higher NIHSS scores (median [IQR], 9 [5-17] vs 7 [4-14]; P < .001), and more frequently underwent endovascular thrombectomy (38% vs 20%; P < .001). The proportion of patients with sICH was 1.8% for tenecteplase and 3.6% for alteplase (P < .001), with an adjusted odds ratio (aOR) of 0.42 (95% CI, 0.30-0.58; P < .01). Similar results were observed in both thrombectomy and nonthrombectomy subgroups. Conclusions and Relevance: In this large study, ischemic stroke treatment with 0.25-mg/kg tenecteplase was associated with lower odds of sICH than treatment with alteplase. The results provide evidence supporting the safety of tenecteplase for stroke thrombolysis in real-world clinical practice.


Subject(s)
Brain Ischemia , Ischemic Stroke , Stroke , Humans , Male , Female , Aged , Aged, 80 and over , Tissue Plasminogen Activator/therapeutic use , Tenecteplase/therapeutic use , Ischemic Stroke/drug therapy , Retrospective Studies , Brain Ischemia/drug therapy , Brain Ischemia/complications , Fibrinolytic Agents , Stroke/drug therapy , Stroke/complications , Intracranial Hemorrhages/etiology , Intracranial Hemorrhages/chemically induced , Treatment Outcome
3.
Cureus ; 13(10): e19086, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34824950

ABSTRACT

Paroxysmal sympathetic hyperactivity (PSH) is a complex and underrecognized phenomenon involving increased sympathetic activity leading to tachycardia, tachypnea, and hypertension. The frequency of nonrecognition is due to a lack of diagnostic criteria. In addition, the lack of evidence-based treatments has further complicated approaches to management. This case describes a patient who presented with a new-onset seizure and intracerebral hemorrhage requiring burst suppression and decompressive craniotomy to attenuate intracranial hypertension (ICH). The patient continued to display paroxysmal dysautonomia requiring a multimodal regimen for control of episodes. He demonstrated neurological improvement and complete resolution of dysautonomic activity prior to being discharged to a rehabilitation facility. A delayed diagnosis, ICH, and refractory PSH status postdecompressive craniotomy presented unique challenges. Given that the number of episodes of paroxysmal "storms" directly correlates with morbidity and mortality, early detection is critical, and lack of recognition makes this a difficult disorder to diagnose and manage.

4.
5.
Med Sci Educ ; 29(1): 35-39, 2019 Mar.
Article in English | MEDLINE | ID: mdl-34457446

ABSTRACT

Limited opportunity for teaching patient-care skills in clinical settings has increased the need for simulation training in medical education. However, this modality may be hard to sustain because of extensive time requirements and potential scheduling conflicts. The authors conducted a pilot randomized study to compare the immediate and long-term effects of using instructional video with self-directed practice to those of using simulation training with expert feedback. The results are promising for the use of instructional video-guided, self-directed deliberate practice; however, future studies with a larger sample from multiple institutions should replicate this study to confirm these results.

6.
Kans J Med ; 11(1): 1-9, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29844852
SELECTION OF CITATIONS
SEARCH DETAIL
...